ORAMED PHARMACEUTICALS INC. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2023-06-30 was $1.77M, a 5.95% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2023-03-31 was $123.00K, a 96.95% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2022-12-31 was $2.35M, a 37.43% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2022-09-30 was $2.86M, a 123.28% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $11.12M.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2021 was $2.69M, a 129.75% increase from fiscal 2020.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2020 was $1.17M, a 45.17% increase from fiscal 2019.
- ORAMED PHARMACEUTICALS INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2019 was $808.00K, a 47.77% decline from fiscal 2018.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2023-06-30 | $1.77M 10-Q · filed 2023-08-10 | $7.10M derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $123.00K 10-Q · filed 2023-05-11 | $7.21M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $11.12M 10-K · filed 2023-03-06 |
| 2022-09-30 | $2.86M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.88M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $4.03M 10-Q · filed 2023-05-11 | |
| 2021-11-30 | $1.71M 10-Q · filed 2022-01-11 | |
| 2021-09-30 | $1.28M 10-Q · filed 2022-11-10 | |
| 2021-08-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.69M 10-K · filed 2023-03-06 |
| 2021-06-30 | $969.00K 10-Q · filed 2022-08-10 | |
| 2021-05-31 | $982.00K 10-Q · filed 2021-07-14 | |
| 2021-03-31 | $647.00K 10-Q · filed 2022-05-12 | |
| 2021-02-28 | $411.00K 10-Q · filed 2021-04-13 | $1.33M derived: sum of 4 quarters · filed 2022-01-11 |
| 2020-11-30 | $317.00K 10-Q · filed 2022-01-11 | $1.21M derived: sum of 4 quarters · filed 2022-01-11 |
| 2020-08-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $1.17M 10-K · filed 2021-11-24 |
| 2020-05-31 | $319.00K 10-Q · filed 2021-07-14 | $1.00M derived: sum of 4 quarters · filed 2021-07-14 |
| 2020-02-29 | $289.00K 10-Q · filed 2021-04-13 | $955.00K derived: sum of 4 quarters · filed 2021-04-13 |
| 2019-11-30 | $280.00K 10-Q · filed 2021-01-14 | $849.00K derived: sum of 4 quarters · filed 2021-01-14 |
| 2019-08-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-24 | $808.00K 10-K · filed 2020-11-24 |
| 2019-05-31 | $271.00K 10-Q · filed 2020-07-07 | $1.04M derived: sum of 4 quarters · filed 2020-07-07 |
| 2019-02-28 | $183.00K 10-Q · filed 2020-04-06 | $1.11M derived: sum of 4 quarters · filed 2020-04-06 |
| 2018-11-30 | $239.00K 10-Q · filed 2020-01-09 | $1.26M derived: sum of 4 quarters · filed 2020-01-09 |
| 2018-08-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27 | $1.55M 10-K · filed 2019-11-27 |
| 2018-05-31 | $346.00K 10-Q · filed 2019-07-10 | $2.13M derived: sum of 4 quarters · filed 2019-11-27 |
| 2018-02-28 | $332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-10 | $1.94M derived: sum of 4 quarters · filed 2019-11-27 |
| 2017-11-30 | $524.00K 10-Q · filed 2019-01-14 | $1.94M derived: sum of 4 quarters · filed 2019-11-27 |
| 2017-08-31 | $933.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27 | $1.57M 10-K · filed 2019-11-27 |
| 2017-05-31 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-07-06 | $686.00K derived: sum of 4 quarters · filed 2018-11-28 |
| 2017-02-28 | $336.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-04-05 | $643.00K derived: sum of 4 quarters · filed 2018-11-28 |
| 2016-11-30 | $158.00K 10-Q · filed 2017-01-11 | $472.00K derived: sum of 4 quarters · filed 2018-11-28 |
| 2016-08-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-28 | $634.00K 10-K · filed 2018-11-28 |
| 2016-05-31 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-07-06 | $908.00K derived: sum of 4 quarters · filed 2017-11-29 |
| 2016-02-29 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-04-06 | $1.27M derived: sum of 4 quarters · filed 2017-11-29 |
| 2015-11-30 | $320.00K 10-Q · filed 2016-01-13 | $1.37M derived: sum of 4 quarters · filed 2017-11-29 |
| 2015-08-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-11-29 | $1.35M 10-K · filed 2017-11-29 |
| 2015-05-31 | $465.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-07-01 | |
| 2015-02-28 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-04-03 | |
| 2014-11-30 | $300.00K 10-Q · filed 2015-01-08 | |
| 2014-08-31 | $1.47M 10-K · filed 2016-11-25 | |
| 2013-08-31 | $719.00K 10-K · filed 2015-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |